Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation (VOM-R01)
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
A PHASE3 clinical study on Atrial Fibrillation and Ventricular Tachycardia, this trial is completed. The trial is conducted by National Heart, Lung, and Blood Institute (NHLBI) and has accumulated 11 data snapshots since 2013. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
Phase: PHASE2/PHASE3 → PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE2_PHASE3
▶ Show 6 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
Status: Active Not Recruiting → Completed
-
Sep 2019 — Oct 2020 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Sep 2018 — Sep 2019 [monthly]
Active Not Recruiting PHASE2_PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2_PHASE3
First recorded
Oct 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Heart, Lung, and Blood Institute (NHLBI)
- National Institutes of Health (NIH)
- The Methodist Hospital Research Institute
For direct contact, visit the study record on ClinicalTrials.gov .